A patient walks into a molecular tumor board with a variant of uncertain significance. The board has thirty minutes. The variant has two million neighbors in ClinVar. OmicsChat knows them all.
The StarGEO Heritage
OmicsChat did not appear from a hackathon. It descended from StarGEO, a platform built at UCSF under NIH BD2K grant UH2CA203792, funded at $634,000 and published in Nature Scientific Data in 2017. StarGEO validated forty-eight disease gene expression signatures against the Gene Expression Omnibus, which holds over 200,000 experimental series from labs around the world. The insight was straightforward: public genomic data is vast, validated, and almost entirely unused by clinicians because nobody built the governed interface between the data and the decision.
OmicsChat is that interface.
The Classification Engine
The core capability is variant classification against the ACMG/AMP framework, the standard of care for clinical genomics. When a genetic counselor or molecular pathologist enters a variant, OmicsChat queries ClinVar (2,000,000+ classified variants), cross-references PharmGKB for pharmacogenomic implications, checks COSMIC for somatic mutation frequency in tumor databases, and returns a structured classification with evidence tier.
| Evidence Tier | Definition | Example |
|---|---|---|
| GOLD | Guideline-backed, multi-source concordance | ClinVar reviewed pathogenic, NCCN-cited |
| SILVER | Published, single authoritative source | PharmGKB Level 1A drug-gene interaction |
| BRONZE | Computational prediction, single study | In silico pathogenicity prediction only |
The tier system is not a UX feature. It is a governance constraint. Every response declares its evidence quality so that clinicians can calibrate their confidence accordingly. A GOLD-tier classification carries different weight in a tumor board than a BRONZE-tier prediction, and OmicsChat makes that distinction explicit in every response.
The Five Omic Domains
OmicsChat covers five domains of molecular medicine, each with its own evidence sources and classification standards.
| Domain | Sources | Clinical Application |
|---|---|---|
| Genomics | ClinVar, GEO, COSMIC | Variant classification, tumor profiling |
| Transcriptomics | GEO, fold-change analysis | Disease signature validation |
| Proteomics | UniProt, PRIDE | Biomarker discovery |
| Pharmacogenomics | PharmGKB, CPIC | Drug-gene interaction, dosing |
| Epigenomics | ENCODE, Roadmap Epigenomics | Methylation, chromatin state |
This is not a literature search engine. It is a governed classification system where every response traces to a specific database, a specific accession number, and a specific evidence tier.
The ABPM Market
The Association for Molecular Pathology sets the professional standard for variant interpretation. Their membership includes the molecular pathologists, genetic counselors, and laboratory directors who run the tests and sign the reports. These professionals do not need another chatbot; they need a governed classification surface that speaks their language, cites their standards, and respects the distinction between research-use and clinical-grade evidence.
OmicsChat is built for this audience. The system prompt enforces ACMG/AMP criteria for every variant classification. It distinguishes research-use from clinical-grade evidence in every response. It cites ClinVar submission counts and review status. It flags variants of uncertain significance with the specific criteria that would reclassify them if new evidence emerges. And it surfaces active clinical trials from ClinicalTrials.gov with NCT numbers, because precision medicine is not just classification; it is connecting patients to the research that might change their classification.
Two-Sided COIN
Community learning is free. A genetic counseling student asks about BRCA2 variant interpretation; OmicsChat responds with ACMG criteria, ClinVar evidence, and NCCN guidelines at no cost. The question joins the community learning ledger, and the pattern compounds. The next student who asks a similar question benefits from the accumulated intelligence.
Professional tiers are earned, not bought. Institutional dashboards for molecular tumor boards, batch classification for laboratory operations, and API access for clinical decision support systems require COIN. The economics follow the work: community education generates intelligence that makes the professional tier more valuable, and the professional tier funds the infrastructure that keeps community learning free.
The Foundation tier provides enterprise capabilities at zero cost for academic medical centers, cancer research institutes, and public health laboratories, because the institutions that train the next generation of molecular pathologists should not have to choose between software budgets and education budgets.
Roadmap
StarGEO resurrection is on the build schedule. The original GEO reanalysis pipeline, which validated forty-eight disease signatures against 200,000+ expression series, will run natively inside OmicsChat. VUS community learning, where variant interpretations from governed sessions compound into a classification intelligence that improves with every question, is the long-term vision. The more clinicians use OmicsChat, the more evidence accumulates, and the more accurate the classifications become.
This is not a feedback loop. It is a governed learning system where every contribution is sourced, every pattern is attributed, and every classification improvement is on the ledger.
Figures
| Context | Type | Data |
|---|---|---|
| post | pipeline | steps: GEO → ClinVar → ACMG/AMP → Evidence Tier → Community Learning |
Sources
| Source | Reference |
|---|---|
| NIH BD2K | UH2CA203792, $634K, StarGEO |
| Nature Scientific Data | StarGEO publication, 2017 |
| ClinVar | ncbi.nlm.nih.gov/clinvar/ — 2M+ variants |
| GEO | ncbi.nlm.nih.gov/geo/ — 200K+ series |
| PharmGKB | pharmgkb.org — Drug-gene interactions |
| COSMIC | cancer.sanger.ac.uk/cosmic — Somatic mutations |
| ACMG/AMP | Standards and guidelines for variant interpretation |
| OmicsChat | hadleylab-canonic/TALKS/OMICSCHAT — precision medicine |
| CANONIC | canonic.org |
| *BLOG | OMICSCHAT | EVERY VARIANT CLASSIFIED. EVERY FINDING EVIDENCED. | 2026-02-16* |